KC1036 vs. chemo for advanced esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study compares a new drug, KC1036, to standard chemotherapy options for people with advanced esophageal squamous cell cancer that has progressed after immunotherapy and at least one chemo. It aims to see if KC1036 works better or has fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your esophageal cancer is the squamous cell type and has spread or come back after treatment.
- You've already had a PD-1/PD-L1 inhibitor and at least one other type of chemo.
- You have at least one tumor that is measurable on a scan (like a CT or MRI).
- You are generally healthy enough to be up and about (ECOG score 0 or 1).
- You weigh at least 40 kg and have a BMI of 16 or higher.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (SYS6010, enlonstobart, and chemotherapy) as a first treatment for people with advanced esophageal cancer that has not spread elsewhere. It aims to find a more effective option for patients who have not received prior therapy for their advanced disease.
This trial studies investigational cancer medicines, either alone or along with pembrolizumab, for people with advanced esophageal squamous cell cancer whose cancer has grown despite prior immune and platinum-based treatment. It may offer a new option after standard therapy has not worked.
This Phase 2 study tests a new immunotherapy drug (candonilimab/AK104) added to chemotherapy before surgery for people with locally advanced esophageal squamous cell carcinoma. It aims to shrink the cancer and improve outcomes by treating it before the operation.
This trial tests a new treatment plan for people with advanced esophageal squamous cell carcinoma that has spread to lymph nodes but not to other organs. It aims to find the best way to treat this cancer using radiation and other therapies.
This trial tests a new drug called KC1036 combined with standard immunotherapy and chemotherapy for people with advanced esophageal cancer that has not been treated before. The goal is to see if this combination can help shrink tumors and improve outcomes.
This early-phase study tests whether KC1036 can treat advanced digestive system cancers that have come back or spread after standard treatment. It may help people by shrinking tumors or slowing growth, and it will also check safety and side effects.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.